Secondary prevention in thrombotic antiphospholipid syndrome

被引：11

作者：

Pengo, V. ^{[1
]}

Denas, G. ^{[1
]}

Banzato, A. ^{[1
]}

Bison, E. ^{[1
]}

Bracco, A. ^{[1
]}

Facchinetti, M. ^{[2
]}

Hoxha, A. ^{[2
]}

Ruffatti, A. ^{[2
]}

机构：

[1] Univ Padua, Thrombosis Ctr, Dept Cardiac Thorac & Vasc Sci, I-35128 Padua, Italy

[2] Univ Padua, Rheumatol Unit, Dept Med, I-35128 Padua, Italy

来源：

LUPUS | 2012年 / 21卷 / 07期

关键词：

antiphospholipid; prevention; drugs; thrombosis; RECURRENT THROMBOSIS; THERAPY; INTENSITY; WARFARIN; RISK;

D O I：

10.1177/0961203312444773

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Secondary prevention of venous thromboembolism in antiphospholipid syndrome (APS) is usually made using vitamin K antagonists (VKAs) to maintain an international normalized ratio (INR) between 2.0 and 3.0. The optimal intensity of anticoagulation was determined in two prospective randomized controlled trials, both excluding the benefit of more intense anticoagulation. The same regimen is also recommended in patients with APS and arterial thromboembolism as aspirin does not appear to protect against recurrences. The duration of treatment is usually indefinite because of a substantial risk of recurrence. Lupus (2012) 21, 734-735.

引用

页码：734 / 735

页数：2

共 50 条

[21] Antiphospholipid syndrome without antiphospholipid antibodies at the time of the thrombotic event: Transient 'seronegative' antiphospholipid syndrome?
Miret, C
Cervera, R
Reverter, JC
GarciaCarrasco, M
Ramos, M
Molla, M
Font, J
Ingelmo, M
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 1997, 15 (05) : 541 - 544
[22] PARALYZED: A RARE CASE OF THROMBOEMBOLISM IN THE SETTING OF NONBACTERIAL THROMBOTIC ENDOCARDITIS SECONDARY TO ANTIPHOSPHOLIPID SYNDROME
Flautt, Thomas
Spangler, Alison
Nickerson, Ashley
Earles, Aaron
Prather, John
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 2304 - 2304
[23] Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome
Arachchillage, D. R. J.
Mackie, I. J.
Efthymiou, M.
Isenberg, D. A.
Machin, S. J.
Cohen, H.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 (07) : 1264 - 1273
[24] Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome
Arachchillage, D. Jayakody
Mackie, I.
Efthymiou, M.
Isenberg, D.
Machin, S.
Cohen, H.
BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 : 10 - 10
[25] Rethinking the use of direct oral anticoagulants for secondary thromboprophylaxis in patients with thrombotic antiphospholipid syndrome
Franco-Moreno, Anabel
Izquierdo-Martinez, Aida
Ancos-Aracil, Cristina
DRUG DISCOVERIES AND THERAPEUTICS, 2024, 18 (04): : 213 - 219
[26] Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome
Arachchillage, D. J.
Mackie, I
Efthymiou, M.
Isenberg, D.
Machin, S.
Cohen, H.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 280 - 280
[27] Urine Proteomics Differentiate Primary Thrombotic Antiphospholipid Syndrome From Obstetric Antiphospholipid Syndrome
Zhou, Zhuochao
You, Yijun
Wang, Fan
Sun, Yue
Teng, Jialin
Liu, Honglei
Cheng, Xiaobing
Su, Yutong
Shi, Hui
Hu, Qiongyi
Chi, Huihui
Jia, Jinchao
Wan, Liyan
Liu, Tingting
Wang, Mengyan
Shi, Ce
Yang, Chengde
Ye, Junna
FRONTIERS IN IMMUNOLOGY, 2021, 12
[28] Antiphospholipid Syndrome and Recurrent Thrombotic Valve Disease
Scantlebury, Dawn C.
Nkomo, Vuyisile T.
Enriquez-Sarano, Maurice
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (23) : E178 - E178
[29] SEROLOGICAL EVOLUTION IN PATIENTS WITH THROMBOTIC ANTIPHOSPHOLIPID SYNDROME
Riancho-Zarrabeitia, L.
Garcia-Canale, S.
Cuberia, M.
Daroca, G.
Agudo, M.
Lopez-Hoyos, M.
Munoz, P.
Martinez-Taboada, V.
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 594 - 594
[30] PRIMARY ANTIPHOSPHOLIPID SYNDROME AND RENAL THROMBOTIC MICROANGIOPATHY
ARA, JM
REYES, MJF
PICAZO, ML
BORREGO, F
ESCUIN, F
SICILIA, LS
NEFROLOGIA, 1991, 11 (04): : 357 - 361

← 1 2 3 4 5 →